JCR Pharmaceuticals Co., Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JP3701000006
JPY
445.00
-9 (-1.98%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationAnnual Results
Results Snapshot
Figures in Million
Consolidate Annual Results
Mar'26
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Net Sales
40,319.00
33,072.00
42,871.00
34,343.00
51,082.00
30,085.00
24,781.00
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
40,319.00
33,072.00
42,871.00
34,343.00
51,082.00
30,085.00
24,781.00
Raw Material Cost
10,259.00
11,093.00
11,620.00
8,886.00
10,461.00
7,812.00
7,901.00
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
398.00
155.00
86.00
44.00
45.00
42.00
22.00
Selling and Distribution Expenses
12,868.00
12,958.00
12,485.00
11,678.00
13,511.00
8,643.00
7,638.00
Other Expenses
1,636.30
1,527.60
1,114.80
875.80
713.00
531.80
597.50
Total Expenditure (Excl Depreciation)
39,888.00
39,482.00
35,339.00
29,366.00
31,147.00
21,815.00
21,536.00
Operating Profit (PBDIT) excl Other Income
431
-6410
7532
4977
19935
8270
3245
Other Income
1,310.00
-482.00
-201.00
480.00
622.00
278.00
68.00
Operating Profit (PBDIT)
4,298.00
-3,518.00
10,528.00
7,454.00
22,502.00
10,440.00
4,747.00
Interest
398.00
155.00
86.00
44.00
45.00
42.00
22.00
Exceptional Items
1,882.00
1,064.00
0.00
0.00
-1,105.00
146.00
131.00
Gross Profit (PBDT)
30,060.00
21,979.00
31,251.00
25,457.00
40,621.00
22,273.00
16,880.00
Depreciation
2,557.00
3,374.00
3,197.00
1,997.00
1,945.00
1,892.00
1,434.00
Profit Before Tax
3,224.00
-5,983.00
7,244.00
5,412.00
19,404.00
8,653.00
3,422.00
Tax
1,017.00
-1,586.00
1,707.00
1,625.00
4,886.00
1,764.00
742.00
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
2,179.00
-4,459.00
5,508.00
3,773.00
14,507.00
6,892.00
2,678.00
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
2,179.00
-4,459.00
5,508.00
3,773.00
14,507.00
6,892.00
2,678.00
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
28.00
63.00
28.00
14.00
10.00
-4.00
1.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
2,207.00
-4,396.00
5,536.00
3,787.00
14,517.00
6,888.00
2,679.00
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Reserves
46,942.00
47,342.00
56,178.00
52,162.00
50,884.00
38,383.00
32,390.00
Earnings per share (EPS)
17.85
-36.02
43.92
30.22
116.79
55.52
21.59
Diluted Earnings per share
17.85
-36.02
43.92
30.22
116.79
55.52
21.59
Operating Profit Margin (Excl OI)
1.07%
-19.38%
17.57%
14.49%
39.03%
27.49%
13.09%
Gross Profit Margin
14.34%
-7.89%
24.35%
21.57%
41.79%
35.05%
19.6%
PAT Margin
5.4%
-13.48%
12.85%
10.99%
28.4%
22.91%
10.81%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Annual Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Mar 2026 is 21.91% vs -22.86% in Mar 2025

stock-summary

Consolidate Net Profit

YoY Growth in year ended Mar 2026 is 150.20% vs -179.41% in Mar 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Mar 2026 is 198.42% vs -128.30% in Mar 2025

stock-summary

Interest

YoY Growth in year ended Mar 2026 is 156.77% vs 80.23% in Mar 2025

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in year ended Mar 2026 has improved from Mar 2025

Compare Annual Results Of JCR Pharmaceuticals Co., Ltd. With
Markets Mojo
Figures in Million
Consolidate Annual Results
Markets Mojo
Markets Mojo
Change(JPY)
Change(%)
Net Sales
40,319.00
2,01,676.00
-1,61,357.00
-80.01%
Other Operating Income
0.00
0.00
0.00
Total Operating income
40,319.00
2,01,676.00
-1,61,357.00
-80.01%
Raw Material Cost
10,259.00
1,42,882.00
-1,32,623.00
-92.82%
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0.00
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
398.00
1,757.00
-1,359.00
-77.35%
Selling and Distribution Expenses
12,868.00
26,056.00
-13,188.00
-50.61%
Other Expenses
1,636.30
1,063.10
573.20
53.92%
Total Expenditure (Excl Depreciation)
39,888.00
1,81,326.00
-1,41,438.00
-78.00%
Operating Profit (PBDIT) excl Other Income
431.00
20,350.00
-19,919.00
-97.88%
Other Income
1,310.00
-341.00
1,651.00
484.16%
Operating Profit (PBDIT)
4,298.00
36,011.00
-31,713.00
-88.06%
Interest
398.00
1,757.00
-1,359.00
-77.35%
Exceptional Items
1,882.00
-3,979.00
5,861.00
147.30%
Gross Profit (PBDT)
30,060.00
58,794.00
-28,734.00
-48.87%
Depreciation
2,557.00
16,002.00
-13,445.00
-84.02%
Profit Before Tax
3,224.00
14,273.00
-11,049.00
-77.41%
Tax
1,017.00
2,737.00
-1,720.00
-62.84%
Provisions and contingencies
0
0
0.00
Profit After Tax
2,179.00
11,536.00
-9,357.00
-81.11%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
2,179.00
11,536.00
-9,357.00
-81.11%
Share in Profit of Associates
0
0
0.00
Minority Interest
28.00
0.00
28.00
Other related items
0.00
0.00
0.00
Consolidated Net Profit
2,207.00
11,536.00
-9,329.00
-80.87%
Equity Capital
0
0
0.00
Face Value
0.00
0.00
0.00
Reserves
46,942.00
1,78,556.00
-1,31,614.00
-73.71%
Earnings per share (EPS)
17.85
90.10
-72.25
-80.19%
Diluted Earnings per share
17.85
90.10
-72.25
-80.19%
Operating Profit Margin (Excl OI)
1.07%
10.09%
0.00
-9.02%
Gross Profit Margin
14.34%
15.01%
0.00
-0.67%
PAT Margin
5.40%
5.72%
0.00
-0.32%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Annual - Net Sales
Net Sales 4,031.90 Million
in Mar 2026

Figures in Million
stock-summary

YoY Growth in year ended Mar 2026 is 21.91% vs -22.86% in Mar 2025

Annual - Consolidate Net Profit
Consolidate Net Profit 220.70 Million
in Mar 2026

Figures in Million
stock-summary

YoY Growth in year ended Mar 2026 is 150.20% vs -179.41% in Mar 2025

Annual - Operating Profit (PBDIT)
Operating Profit (PBDIT) 298.80 Million
in Mar 2026

Figures in Million
stock-summary

YoY Growth in year ended Mar 2026 is 198.42% vs -128.30% in Mar 2025

Annual - Interest
Interest 39.80 Million
in Mar 2026

Figures in Million
stock-summary

YoY Growth in year ended Mar 2026 is 156.77% vs 80.23% in Mar 2025

Annual - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 1.07%
in Mar 2026

Figures in %
stock-summary

YoY Growth in year ended Mar 2026 has improved from Mar 2025